Fetal Therapy for Congenital Pulmonary Malformations: A Prospective Population‐Based National Cohort Study

ABSTRACT Objective To assess the frequency of fetal therapy for fetuses with congenital pulmonary malformations (CPMs) and to investigate their short‐term outcomes. Method The study population included 435 singleton fetuses diagnosed with CPMs from a national population‐based cohort study in France in 2015–2018. Information was obtained from medical records on CPM volume ratio (CVR), signs of compression, fetal therapy and perinatal outcomes. The characteristics and outcomes of fetuses with and without fetal therapy were compared using a univariate test. Results Twenty six fetuses (6.0%, 95% CI: 4.1–8.6) received at least one fetal therapy including thoracoamniotic shunts only ( n = 3), antenatal steroids only ( n = 12), and a combination of several therapies including thoracentesis and amniodrainage, in addition to shunts and steroids ( n = 11). Compared with fetuses without fetal therapy, those who did have higher CVR (1.6 ± 0.3 vs. 0.7 ± 0.04, p < 0.001) and more severe signs of compression (73.1% vs. 12.8%, p < 0.001). The proportion of live births after fetal therapy was 84.6% versus 98.5% ( p < 0.001) for those without fetal therapy and the hospital mortality rate was 13.6% versus 1.0% ( p = 0.004), respectively. Conclusion A small minority of fetuses with CPMs underwent fetal therapy. These patients had a lower survival compared with those who did not receive fetal therapy. Trial Registration NCT02352207